Invasive zygomycosis in neonates and children

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 5, 2009, Pages 50-54

  Roilides, E ^a,b   Zaoutis, T E ^c,d   Walsh, T J ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cutaneus zygomycosis; Gastrointestinal zygomycosis; Mucormycosis; Rhizopus spp

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; POSACONAZOLE; VORICONAZOLE;

ABSIDIA; CHILD; CHILDHOOD MORTALITY; DERMATOMYCOSIS; DRUG SAFETY; FUNGUS CULTURE; GASTROINTESTINAL INFECTION; GRANULOCYTE TRANSFUSION; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INTESTINE RESECTION; LAPAROTOMY; MUCOR; MUCORMYCOSIS; NECROTIZING ENTEROCOLITIS; NEPHROTOXICITY; NEUTROPENIA; NEWBORN; NEWBORN INFECTION; NEWBORN MORTALITY; PREMATURITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHIZOPUS;

RHIZOPUS;

ADOLESCENT; AGE FACTORS; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DEBRIDEMENT; HUMANS; INFANT; INFANT, NEWBORN; RISK FACTORS; ZYGOMYCOSIS;

EID: 70349988093     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02981.x     Document Type: Review

References (23)

1. Roden MM, Zaoutis TE, Buchanan WL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
2. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant centre and review of the literature. Am J Transplant 2006, 6:2365-2374.
3. Kontoyiannis DP, Lionakis MS, Lewis RE. Zygomycosis in a tertiary care cancer centre in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
4. Zaoutis TE, Roilides E, Chiou CC. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007, 26:723-727.
5. Petrikkon GL, Skiiada A, Pagano L. Zygomycosis in Europe: a prospective, epidemiologic study (abstr. M-1845). 48th Interscience conference on Antimicrobial Agents and chemotherapy. Washington DC. 2008
6. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr 2007, 166:1099-1117.
7. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK, Walsh TJ. Zygomycosis in neonates: an uncommon but life threatening infection. Am J Perinatol 2009, epub ahead of print
8. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379-390.
9. Mitchell SJ, Gray J, Morgan ME, Hocking MD, Durbin GM. Nosocomial infection with Rhizopus microsporus in pre-term infants: association with wooden tongue depressors. Lancet 1996, 348:441-443.
10. Kefala-Agoropoulou K, Farmaki E, Tsiouris J, Roilides E, Velegraki A. Cutaneous zygomycosis in an infant with Pearson syndrome. Pediatr Blood Cancer 2008, 50:939-940.
11. Robertson AF, Joshi VV, Ellison DA, Cedars JC. Zygomycosis in neonates. Pediatr Infect Dis J 1997, 16:812-815.
12. Michalak DM, Cooney DR, Rhodes KH, Telander RL, Kleinberg F. Gastrointestinal mucormycoses in infants and children: a cause of gangrenous intestinal cellulitis and perforation. J Pediatr Surg 1980, 15:320-324.
13. Woodward A, McTigue C, Hogg G, Watkins A, Tan H. Mucormycosis of the neonatal gut: a 'new' disease or a variant of necrotizing enterocolitis?. J Pediatr Surg 1992, 27:737-740.
14. Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008, 61(suppl 1):35-40.
15. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005, 11:515-517.
16. Starke JR, Mason EO, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987, 155:766-774.
17. Groll AH, Jaeger G, Allendorf A, Herrmann G, Schloesser R, von Loewenich V. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life [see comments]. Clin Infect Dis 1998, 27:437-452.
18. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007, 8:1167-1178.
19. US Food and Drug Administration. Noxafil® (posaconazole) oral suspension. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=search.label_ApprovalHistory [Accessed 16 August 2009.]
20. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
21. Greenbury RN, Mullane K, van Burik JA. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
22. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005, 40:1684-1688.
23. Raad II, Graybill JR, Bustamante AB. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006, 42:1726-1734.